In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi ...

Ahsan Arozullah, MD, MPH, Senior Vice President and Head of Oncology Development, Astellas "Men with nmHSPC with high-risk biochemical recurrence are very likely to experience disease progression.

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

Pfizer and Astellas are underlining the benefits of Xtandi as part of a combination therapy for certain patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with an overall survival ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

https://www.tipranks.com/news/the-fly/astrazeneca-reports-saphnelo-demonstrates-reduction-in-disease-activity-thefly Astellas Pharma (ALPMY) and Pfizer (PFE ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

XTANDI is a standard of care and has received regulatory approvals in one or more countries around the world for use in men with metastatic hormone-sensitive prostate cancer (mHSPC), metastatic ...

In a wide-ranging sit down during JP Morgan Week in San Francisco, Astellas' chief strategy officer Adam Pearson walked ...

The MarketWatch News Department was not involved in the creation of this content. XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in ...